WUXI BIOLOGICS Revenue vs. Total Debt
| 1FW1 Stock | EUR 4.18 0.08 1.95% |
For WUXI BIOLOGICS profitability analysis, we use financial ratios and fundamental drivers that measure the ability of WUXI BIOLOGICS to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well WUXI BIOLOGICS UNSPADR2 utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between WUXI BIOLOGICS's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of WUXI BIOLOGICS UNSPADR2 over time as well as its relative position and ranking within its peers.
WUXI |
WUXI BIOLOGICS UNSPADR2 Total Debt vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining WUXI BIOLOGICS's current stock value. Our valuation model uses many indicators to compare WUXI BIOLOGICS value to that of its competitors to determine the firm's financial worth. WUXI BIOLOGICS UNSPADR2 is rated below average in revenue category among its peers. It also is rated below average in total debt category among its peers making up about 0.25 of Total Debt per Revenue. The ratio of Revenue to Total Debt for WUXI BIOLOGICS UNSPADR2 is roughly 3.93 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the WUXI BIOLOGICS's earnings, one of the primary drivers of an investment's value.WUXI Revenue vs. Competition
WUXI BIOLOGICS UNSPADR2 is rated below average in revenue category among its peers. Market size based on revenue of Biotechnology industry is presently estimated at about 405.25 Billion. WUXI BIOLOGICS holds roughly 13.09 Billion in revenue claiming about 3% of stocks in Biotechnology industry.
WUXI Total Debt vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
WUXI BIOLOGICS |
| = | 13.09 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
WUXI BIOLOGICS |
| = | 3.33 B |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
WUXI Total Debt vs Competition
WUXI BIOLOGICS UNSPADR2 is rated below average in total debt category among its peers. Total debt of Biotechnology industry is presently estimated at about 106.82 Billion. WUXI BIOLOGICS holds roughly 3.33 Billion in total debt claiming about 3% of stocks in Biotechnology industry.
WUXI BIOLOGICS Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in WUXI BIOLOGICS, profitability is also one of the essential criteria for including it into their portfolios because, without profit, WUXI BIOLOGICS will eventually generate negative long term returns. The profitability progress is the general direction of WUXI BIOLOGICS's change in net profit over the period of time. It can combine multiple indicators of WUXI BIOLOGICS, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
WuXi Biologics Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the Peoples Republic of China, North America, Europe, and internationally. WuXi Biologics Inc. is a subsidiary of WuXi Biologics Holdings Limited. WUXI BIOLOGICS is traded on Frankfurt Stock Exchange in Germany.
WUXI Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on WUXI BIOLOGICS. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of WUXI BIOLOGICS position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the WUXI BIOLOGICS's important profitability drivers and their relationship over time.
Use WUXI BIOLOGICS in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if WUXI BIOLOGICS position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in WUXI BIOLOGICS will appreciate offsetting losses from the drop in the long position's value.WUXI BIOLOGICS Pair Trading
WUXI BIOLOGICS UNSPADR2 Pair Trading Analysis
The ability to find closely correlated positions to WUXI BIOLOGICS could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace WUXI BIOLOGICS when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back WUXI BIOLOGICS - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling WUXI BIOLOGICS UNSPADR2 to buy it.
The correlation of WUXI BIOLOGICS is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as WUXI BIOLOGICS moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if WUXI BIOLOGICS UNSPADR2 moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for WUXI BIOLOGICS can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your WUXI BIOLOGICS position
In addition to having WUXI BIOLOGICS in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Artificial Intelligence Thematic Idea Now
Artificial Intelligence
Technology companies, funds, and ETFs across multiple industries that are involved in research or development in the field of reasoning, learning, natural language processing and perception as well as its application to science and commerce. This theme may also include entities involved in cybernetics and cognitive brain simulation field. The Artificial Intelligence theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Artificial Intelligence Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in WUXI Stock
To fully project WUXI BIOLOGICS's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of WUXI BIOLOGICS UNSPADR2 at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include WUXI BIOLOGICS's income statement, its balance sheet, and the statement of cash flows.